Drug guidance
Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
Condition
Blood and Immune System
Cancer
16 September 2025
-
Published on 4 Jun 2025
Last Updated on 16 Sep 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended epcoritamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. The decision for epcoritamab was based on the uncertainties surrounding its magnitude of clinical benefit, unfavourable cost-effectiveness compared with chemotherapy, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for epcoritamab are provided in the Annex.